Forsteo ® (teriparatid)

För fullständig produktresumé för Forsteo® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Forsteo® (teriparatid): Användning hos patienter med COVID-19

Användning av teriparatid hos patienter med COVID-19 har inte studerats.

Use of Teriparatide in Patients with COVID-19

COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1

Lilly has not studied the use of teriparatide in patients with COVID-19 nor in patients at risk of contracting COVID-19.

Clinicians should use their clinical judgment in determining the most appropriate approach in treating a patient with teriparatide who has confirmed or suspected COVID-19.

Risk of Developing COVID-19 in Patients with Osteoporosis

For further information regarding the risk of contracting coronavirus to people with osteoporosis and those taking osteoporosis medications, please refer to COVID-19 and osteoporosis on the IFO website 2 and local authorities.


Summary of Product Characteristics

According to the prescribing information, Forsteo may cause adverse reactions similar to symptoms of COVID-19. There have been reported adverse reactions in adults in teriparatide clinical trials and post-marketing spontaneous reports:

  • Common (≥ 1/100 to <1/10): Dyspnoea, Fatigue, Chest pain

  • Uncommon (≥ 1/1,000 to <1/100): Emphysema

  • Rare (≥ 1/10,000 to <1/1,000): Possible allergic events soon after injection: acute dyspnoea, oro/facial oedema, generalised urticaria, chest pain, oedema (mainly peripheral).3

Please refer to the Forsteo Summary of Product Characteristics for full prescribing information, including adverse reactions during treatment with teriparatide.

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to

References

1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2. COVID-19 and osteoporosis. International Osteoporosis Foundation. Accessed March 27, 2020. https://www.iofbonehealth.org/news/covid-19-and-osteoporosis

3. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

4. Coronavirus disease (COVID-19) outbreak. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019

5. Coronavirus (COVID-19). Centers for Disease Control and Prevention. Accessed March 17, 2020. https://www.cdc.gov/coronavirus/2019-ncov/index.html

Glossary

CDC = Centers for Disease Control and Prevention

COVID-19 = coronavirus disease 2019

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

WHO = World Health Organization

IFO = International Osteoporosis Foundations

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2020 M03 17


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss